Natural bioactive compounds are considered an excellent alternative strategy for developing effective, safe, and cost-effective antiobesity agents. The aim of this study was to investigate if combinations of soy bean genistein (G), green tea epigallocatechin-3-gallate (E), and/or grape resveratrol (R) at low dosages synergistically inhibit preadipocyte differentiation both in 3T3-L1 cells and human primary preadipocytes (HPAs). Our results show that combinations of G, E, and/or R additively inhibited preadipocyte differentiation (39–56% of control) both in 3T3-L1 cells at 30 μM and HPAs at 15 μM, while the individual compounds have no antiadipogenic effect at the selected concentrations. We also observed similar patterns that combinations of G, E, and/or R additively reduced protein expressions of peroxisome proliferator-activated receptor gamma (PPAR-γ) and CCAAT binding proteins alpha (C/EBP-α), the two key preadipocyte differentiation regulators, both in differentiated 3T3-L1 cells and HPAs. Moreover, combined G, E, and/or R attenuated protein expressions of fatty acid binding protein 4 and perilipin, two PPAR-γ/C/EBP-α downstream molecules in fat drop development in a very similar pattern, in inhibiting differentiation in preadipocytes. This combined antiadipogenic effect of G + E + R is additive, not synergistic according to our results and the Median-Effect Principle. In addition, we found that a lower concentration (15 μM) of G, E, and/or R is required in HPAs than the concentration (30 μM) needed in 3T3-L1 cells, to exert the combined antiadipogenic effect. These data suggest that combinations of G, E, and/or R intake or soy bean, green tea, and/or grape simultaneous consumption may prevent obesity in human being.
Get full access to this article
View all access options for this article.
References
1.
Van HarmelenV, SkurkT, RohrigK, et al.: Effect of BMI and age on adipose tissue cellularity and differentiation capacity in women. Int J Obes Relat Metab Disord, 2003; 27:889–895.
2.
SpaldingKL, ArnerE, WestermarkPO, et al.: Dynamics of fat cell turnover in humans. Nature, 2008; 453:783–787.
3.
FaustIM, JohnsonPR, SternJS, HirschJ: Diet-induced adipocyte number increase in adult rats: A new model of obesity. Am J Physiol, 1978; 235:E279–E286.
4.
HausmanDB, DiGirolamoM, BartnessTJ, HausmanGJ, MartinRJ: The biology of white adipocyte proliferation. Obes Rev, 2001; 2:239–254.
5.
CatenacciVA, WyattHR: The role of physical activity in producing and maintaining weight loss. Nat Clin Pract Endocrinol Metab, 2007; 3:518–529.
6.
YunJW: Possible anti-obesity therapeutics from nature—a review. Phytochemistry. 2010; 71:1625–1641.
7.
SetchellKD, BrownNM, DesaiP, et al.: Bioavailability of pure isoflavones in healthy humans and analysis of commercial soy isoflavone supplements. J Nutr, 2001; 131(4Suppl):1362S–1375S.
8.
YangCS, ChenL, LeeMJ, BalentineD, KuoMC, SchantzSP: Blood and urine levels of tea catechins after ingestion of different amounts of green tea by human volunteers. Cancer Epidemiol Biomarkers Prev, 1998; 7:351–354.
9.
BloedonLT, JeffcoatAR, LopaczynskiW, et al.: Safety and pharmacokinetics of purified soy isoflavones: Single-dose administration to postmenopausal women. Am J Clin Nutr, 2002; 76:1126–1137.
10.
BoocockDJ, FaustGE, PatelKR, et al.: Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev, 2007; 16:1246–1252.
11.
LambertJD, KwonSJ, JuJH, et al.: Effect of genistein on the bioavailability and intestinal cancer chemopreventive activity of (-)-epigallocatechin-3-gallate. Carcinogenesis, 2008; 29:2019–2024.
12.
HsiehTC, WuJM: Targeting CWR22Rv1 prostate cancer cell proliferation and gene expression by combinations of the phytochemicals EGCG, genistein and quercetin. Anticancer Res, 2009; 29:4025–4032.
13.
RayalamS, Della-FeraMA, BaileCA: Synergism between resveratrol and other phytochemicals: Implications for obesity and osteoporosis. Mol Nutr Food Res, 2011; 55:1177–1185.
14.
RayalamS, Della-FeraMA, YangJY, ParkHJ, AmbatiS, BaileCA: Resveratrol potentiates genistein's antiadipogenic and proapoptotic effects in 3T3-L1 adipocytes. J Nutr, 2007; 137:2668–2673.
15.
RayalamS, YangJY, Della-FeraMA, ParkHJ, AmbatiS, BaileCA: Anti-obesity effects of xanthohumol plus guggulsterone in 3T3-L1 adipocytes. J Med Food, 2009; 12:846–853.
16.
YangJY, Della-FeraMA, RayalamS, et al.: Enhanced inhibition of adipogenesis and induction of apoptosis in 3T3-L1 adipocytes with combinations of resveratrol and quercetin. Life Sci, 2008; 82:1032–1039.
17.
ParkHJ, YangJY, AmbatiS, et al.: Combined effects of genistein, quercetin, and resveratrol in human and 3T3-L1 adipocytes. J Mel Food, 2008; 11:773–783.
18.
ZhangM, IkedaK, XuJW, YamoriY, GaoXM, ZhangBL: Genistein suppresses adipogenesis of 3T3-L1 cells via multiple signal pathways. Phytother Res, 2009; 23:713–718.
19.
PapineauD, GagnonA, SoriskyA: Apoptosis of human abdominal preadipocytes before and after differentiation into adipocytes in culture. Metabolism, 2003; 52:987–992.
20.
XuX, HarrisKS, WangHJ, MurphyPA, HendrichS: Bioavailability of soybean isoflavones depends upon gut microflora in women. J Nutr, 1995; 125:2307–2315.
21.
SiH, LiuD: Isoflavone genistein protects human vascular endothelial cells against tumor necrosis factor-alpha-induced apoptosis through the p38beta mitogen-activated protein kinase. Apoptosis, 2009; 14:66–76.
22.
LaiCY, YangJY, RayalamS, et al.: Preventing bone loss and weight gain with combinations of vitamin D and phytochemicals. J Med Food, 2011; 14:1352–1362.
23.
SarkarFH, LiY: Using chemopreventive agents to enhance the efficacy of cancer therapy. Cancer Res, 2006; 66:3347–3350.
24.
MurakamiA, TakahashiD, KoshimizuK, OhigashiH: Synergistic suppression of superoxide and nitric oxide generation from inflammatory cells by combined food factors. Mutat Res, 2003; 523–524:151–161.
25.
DangZC, LowikC: Dose-dependent effects of phytoestrogens on bone. Trends Endocrinol Metab, 2005; 16:207–213.
26.
DangZC: Dose-dependent effects of soy phyto-oestrogen genistein on adipocytes: Mechanisms of action. Obes Rev, 2009; 10:342–349.
27.
PoulsenMM, VestergaardPF, ClasenBF, et al.: High-dose resveratrol supplementation in obese men: An investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes, 2013; 62:1186–1195.
28.
ChowHH, CaiY, HakimIA, et al.: Pharmacokinetics and safety of green tea polyphenols after multiple-dose administration of epigallocatechin gallate and polyphenon E in healthy individuals. Clin Cancer Res, 2003; 9:3312–3319.
29.
KitaniK, OsawaT, YokozawaT: The effects of tetrahydrocurcumin and green tea polyphenol on the survival of male C57BL/6 mice. Biogerontology, 2007; 8:567–573.
30.
ChangHC, ChurchwellMI, DelclosKB, NewboldRR, DoergeDR: Mass spectrometric determination of Genistein tissue distribution in diet-exposed Sprague-Dawley rats. J Nutr, 2000; 130:1963–1970.
31.
SuganumaM, OkabeS, OniyamaM, TadaY, ItoH, FujikiH: Wide distribution of [3H](-)-epigallocatechin gallate, a cancer preventive tea polyphenol, in mouse tissue. Carcinogenesis, 1998; 19:1771–1776.
32.
ZhangY, HendrichS, MurphyPA: Glucuronides are the main isoflavone metabolites in women. J Nutr, 2003; 133:399–404.
33.
ZhangY, SongTT, CunnickJE, MurphyPA, HendrichS: Daidzein and genistein glucuronides in vitro are weakly estrogenic and activate human natural killer cells at nutritionally relevant concentrations. J Nutr, 1999; 129:399–405.
34.
SiH, LiuD: Dietary antiaging phytochemicals and mechanisms associated with prolonged survival. J Nutr Biochem, 2014; 25:581–591.
35.
GummersbachC, HemmrichK, KronckeKD, SuschekCV, FehselK, PalluaN: New aspects of adipogenesis: Radicals and oxidative stress. Differentiation, 2009; 77:115–120.
36.
WangS, Moustaid-MoussaN, ChenL, et al.: Novel insights of dietary polyphenols and obesity. J Nutr Biochem., 25:1–18.
37.
HwangJT, ParkIJ, ShinJI, et al.: Genistein, EGCG, and capsaicin inhibit adipocyte differentiation process via activating AMP-activated protein kinase. Biochem Biophys Res Commun, 2005; 338:694–699.
38.
ChenS, LiZ, LiW, ShanZ, ZhuW: Resveratrol inhibits cell differentiation in 3T3-L1 adipocytes via activation of AMPK. Can J Physiol Pharmacol, 2011; 89:793–799.
39.
KajitaK, MuneT, IkedaT, et al.: Effect of fasting on PPARgamma and AMPK activity in adipocytes. Diabetes Res Clin Pract, 2008; 81:144–149.
40.
DangZC, AudinotV, PapapoulosSE, BoutinJA, LowikCW: Peroxisome proliferator-activated receptor gamma (PPARgamma) as a molecular target for the soy phytoestrogen genistein. J Biol Chem, 2003; 278:962–967.
41.
KimH, SakamotoK: (-)-Epigallocatechin gallate suppresses adipocyte differentiation through the MEK/ERK and PI3K/Akt pathways. Cell Biol Int, 2012; 36:147–153.
42.
LeeH, BaeS, YoonY: The anti-adipogenic effects of (-)epigallocatechin gallate are dependent on the WNT/beta-catenin pathway. J Nutr Biochem, 2013; 24:1232–1240.
43.
CorneliusP, MacDougaldOA, LaneMD: Regulation of adipocyte development. Annu Rev Nutr, 1994; 14:99–129.
44.
EntenmannG, HaunerH: Relationship between replication and differentiation in cultured human adipocyte precursor cells. Am J Physiol-Cell Physiol, 1996; 270:C1011–C1016.
45.
ChouTC: Preclinical versus clinical drug combination studies. Leuk Lymphoma, 2008; 49:2059–2080.
46.
ChouTC, TalalayP: Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul, 1984; 22:27–55.
